Michael Tachezy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael Tachezy has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Jakob R. Izbicki
Abteilung für Allgemein und Viszeralchirurgie, BG Klinikum Hamburg, Hamburg, Deutschland
3 shared publications- Jakob Robert Izbicki
Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
3 shared publications F. Gebauer
Universitätsklinikum Hamburg-Eppendorf
2 shared publicationsFlorian Gebauer
Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
2 shared publications- Florian Gebauer
Universitätsklinikum Hamburg-Eppendorf
2 shared publications I. Anusic
Universitätsklinikum Hamburg-Eppendorf
2 shared publications
Latest Publications
- Open Access
- 1 April 2021
- Published by Springer Nature in Der Chirurg
- Vol. 92 (6) , 550
Erratum zu: Der querschnittgelähmte Patient. Besonderheiten der viszeralchirurgischen Diagnostik und Therapie
Ein Erratum zu dieser Publikation wurde veröffentlicht: 10.1007/s00104-021-01364-2
- 1 April 2021
- Published by Springer Nature in Der Chirurg
- Vol. 92 (6) , 550
Open AccessErratum zu: Der querschnittgelähmte Patient. Besonderheiten der viszeralchirurgischen Diagnostik und Therapie
Ein Erratum zu dieser Publikation wurde veröffentlicht: 10.1007/s00104-021-01364-2
- Open Access
- 25 February 2021
- Published by Springer Nature in Der Chirurg
- Vol. 92 (6) , 551-558
Der querschnittgelähmte Patient – Besonderheiten der viszeralchirurgischen Diagnostik und Therapie
Zusammenfassung Hintergrund Patienten mit einer Querschnittlähmung entwickeln syndromspezifische, viszeralchirurgisch relevante Krankheitsbilder, die im Rahmen des akuten spinalen Schocks auftreten können oder Folge der zumeist progredienten neurogenen Darmfunktionsstörung (NBD) mit Ausbildung eines Colon elongatum und/oder Megakolons sind. Auch die akuten abdominalchirurgischen Notfälle, wie akute Appendizitis, Cholezystitis, Divertikultis oder Ileusbilder, stellen den Kliniker bei untypischer oder teils fehlender Klinik vor diagnostische und therapeutische Herausforderungen. Einen zunehmenden Stellenwert nimmt die Ausweitung adipositaschirurgischer Indikationen auf Patienten mit einer Querschnittlähmung ein Ziel der Arbeit Dieser Artikel soll einen Überblick über die speziellen Anforderungen und Aspekte in der Behandlung dieses speziellen Patientenkollektivs geben und die Evidenz querschnittspezifischer viszeralchirurgischer Behandlungen aufzeigen. Material und Methoden Es wurde eine selektive Literaturrecherche in den Datenbanken Medline und Cochrane Library in deutscher und englischer Sprache (1985–2020) durchgeführt. Ergebnisse und Diskussion Die klinische Behandlung querschnittgelähmter Patienten erfordert einen profunden Kenntnisstand über die pathophysiologischen Veränderungen bei unterschiedlicher Querschnitthöhe (oberes vs. unteres motorisches Neuron) und die Phasen der Erkrankung (spinaler Schock vs. Langzeitverlauf). Fehlende oder atypische klinische Symptome akuter Erkrankungen verzögern eine rasche Diagnosefindung und machen eine frühzeitige Durchführung gezielter Diagnostik unabdingbar. Die Evidenz der chirurgischen Behandlung der akuten und chronischen Folgen der NBD ist gering und basiert auf Fallserien und „case reports“ ebenso wie die für spezielle Indikationen wie adipositaschirurgische Eingriffe.
- 25 February 2021
- Published by Springer Nature in Der Chirurg
- Vol. 92 (6) , 551-558
Open AccessDer querschnittgelähmte Patient – Besonderheiten der viszeralchirurgischen Diagnostik und Therapie
Zusammenfassung Hintergrund Patienten mit einer Querschnittlähmung entwickeln syndromspezifische, viszeralchirurgisch relevante Krankheitsbilder, die im Rahmen des akuten spinalen Schocks auftreten können oder Folge der zumeist progredienten neurogenen Darmfunktionsstörung (NBD) mit Ausbildung eines Colon elongatum und/oder Megakolons sind. Auch die akuten abdominalchirurgischen Notfälle, wie akute Appendizitis, Cholezystitis, Divertikultis oder Ileusbilder, stellen den Kliniker bei untypischer oder teils fehlender Klinik vor diagnostische und therapeutische Herausforderungen. Einen zunehmenden Stellenwert nimmt die Ausweitung adipositaschirurgischer Indikationen auf Patienten mit einer Querschnittlähmung ein Ziel der Arbeit Dieser Artikel soll einen Überblick über die speziellen Anforderungen und Aspekte in der Behandlung dieses speziellen Patientenkollektivs geben und die Evidenz querschnittspezifischer viszeralchirurgischer Behandlungen aufzeigen. Material und Methoden Es wurde eine selektive Literaturrecherche in den Datenbanken Medline und Cochrane Library in deutscher und englischer Sprache (1985–2020) durchgeführt. Ergebnisse und Diskussion Die klinische Behandlung querschnittgelähmter Patienten erfordert einen profunden Kenntnisstand über die pathophysiologischen Veränderungen bei unterschiedlicher Querschnitthöhe (oberes vs. unteres motorisches Neuron) und die Phasen der Erkrankung (spinaler Schock vs. Langzeitverlauf). Fehlende oder atypische klinische Symptome akuter Erkrankungen verzögern eine rasche Diagnosefindung und machen eine frühzeitige Durchführung gezielter Diagnostik unabdingbar. Die Evidenz der chirurgischen Behandlung der akuten und chronischen Folgen der NBD ist gering und basiert auf Fallserien und „case reports“ ebenso wie die für spezielle Indikationen wie adipositaschirurgische Eingriffe.
- 1 August 2016
- Vol. 36 (8) , 3991-5
Prognostic Impact of Activated Leucocyte Cell Adhesion Molecule (ALCAM/CD166) in Infantile Neuroblastoma.
Activated leukocyte cell adhesion molecule (ALCAM/CD166) as a member of the 'immunoglobulin superfamily' is known to be involved in cancer cell proliferation and migration. The aim of this study was to investigate the expression of ALCAM in neuroblastoma tissues. ALCAM expression was analyzed in primary neuroblastoma specimens by immunohistochemistry on microarray sections. Histopathological and clinical data were correlated with ALCAM expression and survival analysis was performed. Sixty-six children were included in the study. Strong expression of ALCAM was detected in 52 (79%) of the samples. Weak expression was significantly correlated with the International Neuroblastoma Staging System (INSS) stage (p=0.024) and positive n-MYC amplification (p=0.019). Recurrence-free survival (RFS) and overall survival (OS) were significantly shorter if ALCAM was expressed weakly (p=0.032 and p=0.001). Weak ALCAM expression was significantly correlated with established markers for poor prognosis, as well as shorter RFS and OS. ALCAM might be considered as a prognostic marker for infantile neuroblastoma.
- 1 August 2016
- Vol. 36 (8) , 3991-5
Prognostic Impact of Activated Leucocyte Cell Adhesion Molecule (ALCAM/CD166) in Infantile Neuroblastoma.
Activated leukocyte cell adhesion molecule (ALCAM/CD166) as a member of the 'immunoglobulin superfamily' is known to be involved in cancer cell proliferation and migration. The aim of this study was to investigate the expression of ALCAM in neuroblastoma tissues. ALCAM expression was analyzed in primary neuroblastoma specimens by immunohistochemistry on microarray sections. Histopathological and clinical data were correlated with ALCAM expression and survival analysis was performed. Sixty-six children were included in the study. Strong expression of ALCAM was detected in 52 (79%) of the samples. Weak expression was significantly correlated with the International Neuroblastoma Staging System (INSS) stage (p=0.024) and positive n-MYC amplification (p=0.019). Recurrence-free survival (RFS) and overall survival (OS) were significantly shorter if ALCAM was expressed weakly (p=0.032 and p=0.001). Weak ALCAM expression was significantly correlated with established markers for poor prognosis, as well as shorter RFS and OS. ALCAM might be considered as a prognostic marker for infantile neuroblastoma.
- 30 October 2015
- Published by Springer Nature in Der Chirurg
- Vol. 86 (11) , 1081
Erratum zu: Perioperative CRP-Bestimmung bei der Appendektomie
- 30 October 2015
- Published by Springer Nature in Der Chirurg
- Vol. 86 (11) , 1081
Erratum zu: Perioperative CRP-Bestimmung bei der Appendektomie
- 25 January 2015
- Published by Springer Nature in Der Chirurg
- Vol. 86 (9) , 881-888
Perioperative CRP-Bestimmung bei der Appendektomie
- 25 January 2015
- Published by Springer Nature in Der Chirurg
- Vol. 86 (9) , 881-888
Perioperative CRP-Bestimmung bei der Appendektomie
- Open Access
- 20 June 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (6) , e39018
ALCAM (CD166) Expression and Serum Levels in Pancreatic Cancer
This study was conducted to evaluate the expression of the activated leukocyte cell adhesion molecule (ALCAM) in pancreatic cancer (PAC) and to determine whether or not the ectodomain shedding of ALCAM (s-ALCAM) could serve as a biomarker in the peripheral blood of PAC patients. Tissue specimens and blood sera of patients with PAC (n = 264 and n = 116, respectively) and the sera of 115 patients with chronic pancreatitis (CP) were analyzed via ALCAM immunohistochemistry and s-ALCAM ELISA tests. Results were correlated with clinical, histopathological, and patient survival data (Chi-square test, Kaplan-Meier analysis, log-rank test, respectively). ALCAM was expressed in the majority of PAC lesions. Immunohistochemistry and serum ELISA tests revealed no association between ALCAM expression in primary tumors or s-ALCAM and clinical or histopathological data. Neither ALCAM nor s-ALCAM showed a significant impact regarding overall survival (p = 0.261 and p = 0.660, respectively). S-ALCAM serum levels were significantly elevated compared to the sera of CP patients (p<0.001). The sensitivity of s-ALCAM in detecting PAC was 58.6% at a specificity of 73.9% (AUC = 0.69). ALCAM is expressed in the majority of PAC lesions, but statistical analysis revealed no association with clinical or pathological data. Although significantly elevated in patients with PAC, the sensitivity and specificity of the s-ALCAM serum quantification test was low. Therefore, its potential as a novel diagnostic marker for PAC remains elusive and further investigations are required.
- 20 June 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (6) , e39018
Open AccessALCAM (CD166) Expression and Serum Levels in Pancreatic Cancer
This study was conducted to evaluate the expression of the activated leukocyte cell adhesion molecule (ALCAM) in pancreatic cancer (PAC) and to determine whether or not the ectodomain shedding of ALCAM (s-ALCAM) could serve as a biomarker in the peripheral blood of PAC patients. Tissue specimens and blood sera of patients with PAC (n = 264 and n = 116, respectively) and the sera of 115 patients with chronic pancreatitis (CP) were analyzed via ALCAM immunohistochemistry and s-ALCAM ELISA tests. Results were correlated with clinical, histopathological, and patient survival data (Chi-square test, Kaplan-Meier analysis, log-rank test, respectively). ALCAM was expressed in the majority of PAC lesions. Immunohistochemistry and serum ELISA tests revealed no association between ALCAM expression in primary tumors or s-ALCAM and clinical or histopathological data. Neither ALCAM nor s-ALCAM showed a significant impact regarding overall survival (p = 0.261 and p = 0.660, respectively). S-ALCAM serum levels were significantly elevated compared to the sera of CP patients (p<0.001). The sensitivity of s-ALCAM in detecting PAC was 58.6% at a specificity of 73.9% (AUC = 0.69). ALCAM is expressed in the majority of PAC lesions, but statistical analysis revealed no association with clinical or pathological data. Although significantly elevated in patients with PAC, the sensitivity and specificity of the s-ALCAM serum quantification test was low. Therefore, its potential as a novel diagnostic marker for PAC remains elusive and further investigations are required.
- Open Access
- 17 November 2010
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 4 (1) , 368
Omental infarction in the postpartum period: a case report and a review of the literature
Omental infarction is a rare and often misdiagnosed clinical event with unspecific symptoms. It affects predominantly young and middle aged women.
- 17 November 2010
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 4 (1) , 368
Open AccessOmental infarction in the postpartum period: a case report and a review of the literature
Omental infarction is a rare and often misdiagnosed clinical event with unspecific symptoms. It affects predominantly young and middle aged women.
- 1 October 2010
- Vol. 25 (10) , 1239-46
Angiogenesis index CD105 (endoglin)/CD31 (PECAM-1) as a predictive factor for invasion and proliferation in intraductal papillary mucinous neoplasm (IPMN) of the pancreas.
Intraductal papillary-mucinous neoplasm (IPMN) of the pancreas is an increasingly diagnosed entity since its definition by the World Health Organization in 1996. It has a broad clinical spectrum ranging from benign to malignant tumors. Optimum treatment is controversial and a better understanding of the development of IPMN of the pancreas and identification of potential prognostic factors will help to address this. Angiogenesis plays an elementary role in the development of malignant tumors and may well also be important in the development of IPMN of the pancreas. Therefore we investigated endothelial cell marker CD31 (PECAM-1) and angiogenesis associated marker CD105 (endoglin) by immunohistochemistry. Thirty-two cases of surgically resected IPMN were chosen retrospectively and clinical data were obtained. Specimens were stained for proliferation marker (Ki-67), CD31 and CD105 by immunohistochemistry. A CD105/CD31 Angiogenesis ratio (AR) was established to determine the proliferating fraction of endothelial cells. The AR is significantly elevated in invasive IPMN of the pancreas (Mann-Whitney-U Test, p<0.05) and is associated with the Ki-67-labelling-index, demonstrating synergy between tumor-growth and neovascularisation. Invasive IPMN of the pancreas is associated with significantly lower recurrence-free and overall survival. Neovascularisation plays an important role in the tumorigenesis of invasive IPMN of the pancreas, and therefore angiogenesis-associated molecules like CD105 and CD31 might be useful tools as prognostic markers. Furthermore, the results indicate a potential role for adjuvant anti-angiogenic therapies in selected patients with recurring and/or invasive IPMN of the pancreas.
- 1 October 2010
- Vol. 25 (10) , 1239-46
Angiogenesis index CD105 (endoglin)/CD31 (PECAM-1) as a predictive factor for invasion and proliferation in intraductal papillary mucinous neoplasm (IPMN) of the pancreas.
Intraductal papillary-mucinous neoplasm (IPMN) of the pancreas is an increasingly diagnosed entity since its definition by the World Health Organization in 1996. It has a broad clinical spectrum ranging from benign to malignant tumors. Optimum treatment is controversial and a better understanding of the development of IPMN of the pancreas and identification of potential prognostic factors will help to address this. Angiogenesis plays an elementary role in the development of malignant tumors and may well also be important in the development of IPMN of the pancreas. Therefore we investigated endothelial cell marker CD31 (PECAM-1) and angiogenesis associated marker CD105 (endoglin) by immunohistochemistry. Thirty-two cases of surgically resected IPMN were chosen retrospectively and clinical data were obtained. Specimens were stained for proliferation marker (Ki-67), CD31 and CD105 by immunohistochemistry. A CD105/CD31 Angiogenesis ratio (AR) was established to determine the proliferating fraction of endothelial cells. The AR is significantly elevated in invasive IPMN of the pancreas (Mann-Whitney-U Test, p<0.05) and is associated with the Ki-67-labelling-index, demonstrating synergy between tumor-growth and neovascularisation. Invasive IPMN of the pancreas is associated with significantly lower recurrence-free and overall survival. Neovascularisation plays an important role in the tumorigenesis of invasive IPMN of the pancreas, and therefore angiogenesis-associated molecules like CD105 and CD31 might be useful tools as prognostic markers. Furthermore, the results indicate a potential role for adjuvant anti-angiogenic therapies in selected patients with recurring and/or invasive IPMN of the pancreas.
- Open Access
- 2 December 2009
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 9 (1) , 194
Abscess of adrenal gland caused by disseminated subacute Nocardia farcinica pneumonia. A case report and mini-review of the literature
Infections caused by Nocardia farcinica are uncommon and show a great variety of clinical manifestations in immunocompetent and immunocompromised patients. Because of its unspecific symptoms and tendency to disseminate it may mimic the clinical symptoms and radiologic findings of a tumour disease and the diagnosis of nocardiosis can easily be missed, because there are no characteristic symptoms.
- 2 December 2009
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 9 (1) , 194
Open AccessAbscess of adrenal gland caused by disseminated subacute Nocardia farcinica pneumonia. A case report and mini-review of the literature
Infections caused by Nocardia farcinica are uncommon and show a great variety of clinical manifestations in immunocompetent and immunocompromised patients. Because of its unspecific symptoms and tendency to disseminate it may mimic the clinical symptoms and radiologic findings of a tumour disease and the diagnosis of nocardiosis can easily be missed, because there are no characteristic symptoms.